Novartis’s $900 Million BoomRay Licence Names No Target, No Isotope and No Upfront
Without an upfront, a target or an isotope, BoomRay’s $900 million headline is a ceiling rather than a valuation.
Radiopharma
Telix Is Paying $1.65 Billion for ITM Without Handing the Sellers Any Cash at Closing
The sellers receive shares, not cash, at closing, and $450m of the $700m earnout rests on a single year of sales.
Years After NCCN Recommended It, FET-PET Finally Has an FDA-Approved Drug
The clinical case was settled before the regulatory one. Clinicians held an NCCN recommendation with no lawful product to act on it.
ITM’s Complete Response Letter Names No Clinical Concern. It Names a Third-Party Facility.
COMPETE hit its endpoint and is published in The Lancet. The FDA did not touch any of it. What stopped the approval is a facility ITM does not own.
Curium’s CVR Waterfall Says It Trusts DEFINITY, Is Betting on Neurology, and Doubts Prostate
Curium locked 89.5% of consideration in cash and hung the rest on prostate. The CVR waterfall is the buyer’s own forecast, published.